NanoViricides Inc. Common Stock (NNVC)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor in the Buffett-Graham tradition, I start with business quality and a margin of safety. NanoViricides is a clinical-stage nano-biopharmaceutical company with only 7 employees, and the filed figures show no revenue. In fiscal 2026, the year ended 2026-06-30, net loss was $8.2 million and diluted EPS was -$0.41. In fiscal 2025, the year ended 2025-06-30, net loss was $9.5 million and diluted EPS was -$0.63. In fiscal 2024, the year ended 2024-06-30, net loss was $8.3 million and diluted EPS was -$0.70. The fiscal 2026 loss narrowed, but the company still burns cash: trailing free cash flow was -$7.4 million, a -21.9% FCF yield on a $33.7 million market cap. At the 2026-10-13 close of $1.32, FairStock calculations show a P/E of -3.22, P/B of 3.47, ROE of -101.46%, ROCE of -55.53%, Piotroski F-Score of 0/9, Altman Z-Score of -1.97, and FairStock Score of 26/100. The Lynch category is none because it lost money in each of the last four years. The pipeline — NV-387 for RSV and influenza, plus COVID formulations — has completed Phase 1a/1b safety testing, but that is far from commercial proof. Without revenue, earnings, or a durable moat I can measure, the $33.7 million value rests mostly on hope for clinical success. Graham would call this speculation rather than investment. The price may not look cheap once the cash burn and binary trial risk are weighed.

In plain English: NanoViricides is a tiny clinical-stage drug developer with no product sales, trying to create antiviral treatments. It has lost money every year in the figures provided, and its main drug candidate is still in early human testing. At $1.32 a share, the price looks expensive relative to its current financial results, though the value ultimately depends on whether the science succeeds.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer